Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Dollar change +0.02
Percentage change 1.09	%

Held by: ARKK ARKG VTI VB IWM VBR VXF IBB SCHA IWO

Index	RUT	P/E	-	EPS (ttm)	-1.14	Insider Own	3.58%	Shs Outstand	267.74M	Perf Week	-14.60%
Market Cap	509.37M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	-2.10%	Shs Float	262.61M	Perf Month	37.51%
Income	-296.90M	PEG	-	EPS next Q	-0.23	Inst Own	92.41%	Short Float	20.11%	Perf Quarter	-63.40%
Sales	200.43M	P/S	2.54	EPS this Y	23.50%	Inst Trans	-6.30%	Short Ratio	4.87	Perf Half Y	-77.41%
Book/sh	2.38	P/B	0.78	EPS next Y	21.10%	ROA	-16.65%	Short Interest	52.82M	Perf Year	-85.11%
Cash/sh	2.06	P/C	0.91	EPS next 5Y	-1.00%	ROE	-44.28%	52W Range	1.25 - 14.55	Perf YTD	-80.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.76%	ROI	-18.90%	52W High	-87.15%	Beta	2.01
Dividend TTM	-	Quick Ratio	8.36	Sales past 5Y	24.48%	Gross Margin	17.49%	52W Low	49.62%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	9.28	EPS Y/Y TTM	18.48%	Oper. Margin	-156.06%	RSI (14)	42.69	Volatility	9.43% 13.48%
Employees	796	Debt/Eq	1.44	Sales Y/Y TTM	49.54%	Profit Margin	-148.13%	Recom	2.21	Target Price	3.27
Option/Short	Yes / Yes	LT Debt/Eq	1.42	EPS Q/Q	20.24%	Payout	-	Rel Volume	1.20	Prev Close	1.85
Sales Surprise	-10.66%	EPS Surprise	-5.26%	Sales Q/Q	-0.23%	Earnings	May 09 AMC	Avg Volume	10.85M	Price	1.87
SMA20	2.41%	SMA50	-27.39%	SMA200	-72.27%	Trades		Volume	10,738,979	Change	1.09%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Downgrade	JP Morgan	Overweight → Neutral
Apr-18-24	Downgrade	Goldman	Buy → Neutral	$7 → $2.50
Dec-14-23	Initiated	Stephens	Overweight	$11
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-17-23	Upgrade	UBS	Neutral → Buy	$13 → $10
Oct-31-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$11
Sep-28-23	Initiated	Bernstein	Outperform	$11
Jul-05-23	Resumed	JP Morgan	Overweight	$13
Jun-30-23	Initiated	Goldman	Buy	$17
May-10-23	Initiated	Barclays	Equal Weight	$14
Mar-31-23	Upgrade	TD Cowen	Market Perform → Outperform	$13 → $15
Feb-02-23	Initiated	UBS	Neutral	$13
Jan-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$12
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$12
Jan-21-22	Resumed	Cantor Fitzgerald	Overweight	$62 → $31
Jan-06-22	Resumed	Piper Sandler	Neutral	$20
Oct-15-21	Resumed	Cowen	Market Perform	$30
Sep-27-21	Initiated	Canaccord Genuity	Buy	$45
Feb-11-21	Upgrade	Piper Sandler	Neutral → Overweight	$20 → $52

Show Previous Ratings

Today 09:00AM	Pacific Biosciences of California, Inc. (PACB) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
May-15-24 11:53AM	Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes (MT Newswires)
10:48AM	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating (MT Newswires)
09:45AM	Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases (PR Newswire)
May-14-24 03:46AM	Pacific Biosciences to lay off 195 employees as part of cost cuts (MedTech Dive) +15.54%
09:47AM	Loading…
May-13-24 09:47AM	Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating (MT Newswires) +9.04%
May-10-24 06:32PM	Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:43PM	Pacific Biosciences of California Inc (PACB) Q1 2024 Earnings: Narrowing Losses but Misses ... (GuruFocus.com)
11:16AM	PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up (Zacks)
May-09-24 08:55PM	PACB Stock Earnings: Pacific Biosciences Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:30PM	Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:10PM	Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:04PM	Pacific Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	PacBio Announces First Quarter 2024 Financial Results (PR Newswire)
May-07-24 12:12PM	Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings (Zacks) -6.03%
09:00AM	Loading…
May-02-24 09:00AM	Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know (Zacks)
Apr-25-24 09:35AM	Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks (Zacks)
Apr-23-24 12:00PM	Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Apr-17-24 01:00PM	PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays (Zacks)
Apr-16-24 02:47PM	The Cathie Wood Stock Shuffle: 4 Names Shes Loving, 3 Shes Leaving (InvestorPlace) -50.62%
08:05AM	PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance (PR Newswire)
Apr-03-24 10:54AM	Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now (Zacks)
Mar-27-24 08:00AM	Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes (PR Newswire) +5.68%
Mar-22-24 04:30PM	PacBio Grants Equity Incentive Award to New Employee (PR Newswire)
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey) +5.74%
10:17AM	PacBio's (PACB) New Panel to Aid Its Clinical Research Solution (Zacks)
Mar-12-24 09:05AM	PacBio Announces PureTarget Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions (PR Newswire) -8.86%
Mar-06-24 11:57PM	Director David Meline Acquires 40,000 Shares of Pacific Biosciences of California Inc (PACB) (GuruFocus.com)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey) +7.46%
Feb-26-24 04:05PM	PacBio to Present at Upcoming Investor Conferences (PR Newswire)
07:04AM	Loading…
Feb-25-24 07:04AM	14 Best Beaten Down Stocks To Buy Right Now (Insider Monkey)
Feb-22-24 04:21AM	13 Best Falling Stocks To Buy Right Now (Insider Monkey)
Feb-16-24 10:50AM	PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down (Zacks) -13.94%
08:59AM	Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:34AM	Q4 2023 Pacific Biosciences of California Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-15-24 06:30PM	Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:30PM	Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:43PM	Pacific Biosciences of California Inc (PACB) Reports Substantial Revenue Growth Amidst Widening ... (GuruFocus.com)
04:28PM	Pacific Biosciences: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results (PR Newswire)
Feb-13-24 07:00AM	Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch (PR Newswire) -9.39%
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-06-24 09:41AM	PacBio's (PACB) New Kits to Boost Its Revio Sequencing System (Zacks)
Feb-05-24 09:05AM	PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale (PR Newswire)
Jan-25-24 04:03PM	PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024 (PR Newswire)
Jan-16-24 12:13PM	PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction (Zacks)
Jan-15-24 09:05AM	PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions (PR Newswire)
Jan-11-24 10:00AM	TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors (PR Newswire) -12.06%
Jan-09-24 10:43AM	PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales (Zacks)
Jan-08-24 08:00AM	PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively (PR Newswire) -18.51%
Dec-27-23 04:05PM	PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-26-23 08:24AM	Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now (Zacks)
Dec-20-23 01:50PM	12 Most Promising Gene Editing Stocks According to Hedge Funds (Insider Monkey)
Dec-11-23 08:00AM	PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors (PR Newswire)
Dec-10-23 04:00PM	The 3 Best Cathie Wood Stocks to Buy in December (InvestorPlace)
11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Nov-10-23 09:30AM	Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics (Zacks)
Nov-09-23 04:10PM	PacBio to Present at Upcoming Investor Conferences (PR Newswire)
Nov-02-23 09:05AM	PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders (PR Newswire) +9.21%
Nov-01-23 09:05AM	PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible (PR Newswire)
Oct-31-23 11:35AM	PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View (Zacks) -13.08%
09:34AM	Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:05AM	PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications (PR Newswire)
Oct-30-23 06:00PM	Pacific Biosciences of California Inc (PACB) Reports Q3 2023 Earnings: Revenue Up 72% YoY (GuruFocus.com)
04:19PM	Pacific Biosciences: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	PacBio Announces Third Quarter 2023 Financial Results (PR Newswire)
03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-18-23 05:52AM	Cathie Wood Just Added $5 Million of This Stock After It Had a Steep Pullback. Is It a No-Brainer Buy? (Motley Fool) -6.82%
Oct-17-23 10:04AM	PacBio's (PACB) New Offering to Boost WGS Data Analysis (Zacks)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
08:05AM	PacBio Announces Appointment of David Meline to Board of Directors (PR Newswire)
Oct-12-23 04:03PM	PacBio to Report Third Quarter 2023 Financial Results on October 30, 2023 (PR Newswire) -10.96%
Oct-11-23 09:05AM	PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis (PR Newswire)
Oct-06-23 12:11PM	Three Reasons to Add PacBio (PACB) Stock to Your Portfolio (Zacks)
Sep-19-23 12:07PM	Unraveling the Challenges Ahead for Pacific Biosciences of California Inc (PACB) (GuruFocus.com)
Sep-18-23 11:55AM	Is Pacific Biosciences of California (PACB) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com) -7.10%
Sep-14-23 12:56PM	Unveiling Pacific Biosciences of California (PACB)'s Value: Is It Really Priced Right? A ... (GuruFocus.com) -6.06%
12:32PM	Unraveling the Challenges Ahead for Pacific Biosciences of California Inc (PACB) (GuruFocus.com)
07:30AM	Strength Seen in Pacific Biosciences (PACB): Can Its 8.9% Jump Turn into More Strength? (Zacks)
Sep-13-23 12:48PM	Pacific Biosciences of California Stock Clears Key Benchmark, Hitting 80-Plus RS Rating (Investor's Business Daily) +8.92%
Sep-12-23 08:00AM	PacBio Announces PacBio Capital (PR Newswire)
Sep-08-23 07:23AM	Cathie Wood's Buying These 3 Stocks Hand Over Fist (Motley Fool)
Sep-07-23 09:05AM	PacBio Announces Collaboration with Leading Library Preparation Automation Partners (PR Newswire)
Sep-05-23 12:25PM	Here's Why You Should Retain PacBio (PACB) Stock for Now (Zacks)
09:52AM	Market May Be Broadening Out: Cathie Wood Loads Up on These 2 Innovation Stocks (TipRanks)
Aug-09-23 04:03PM	PacBio to Present at Upcoming Investor Conferences (PR Newswire)
10:00AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
08:16AM	PacBio (PACB) Inks Research Collaboration for Genome Sequencing (Zacks)
Aug-07-23 09:18AM	Time to Nail Down Profits in One of My Top Picks (TheStreet.com)
08:00AM	PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care (PR Newswire)
Aug-04-23 07:20PM	PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.73%
08:30AM	Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S Is On The Mark (Simply Wall St.)
Aug-03-23 01:16PM	PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View (Zacks) -7.99%
Aug-02-23 06:15PM	Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.15%
05:06PM	Pacific Biosciences: Q2 Earnings Snapshot (AP Finance)
04:06PM	PacBio Announces Second Quarter 2023 Financial Results (PR Newswire)
04:04PM	PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer (PR Newswire)
04:02PM	PacBio Begins Commercialization of the Onso Short-Read Sequencing System (PR Newswire)
Jul-26-23 10:02AM	Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-19-23 04:05PM	PacBio to Report Second Quarter 2023 Financial Results on August 2, 2023 (PR Newswire)

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farmer Michele	See Remarks	May 20 '24	Sale	2.03	5,275	10,708	211,941	May 22 05:25 PM
ORDONEZ KATHY	Director	Mar 15 '24	Option Exercise	2.87	361,621	1,038,682	380,216	Mar 19 04:24 PM
Meline David W	Director	Mar 06 '24	Buy	4.40	40,000	176,160	40,000	Mar 06 05:36 PM
HENRY CHRISTIAN O	See Remarks	Mar 04 '24	Sale	4.87	14,177	69,056	2,596,670	Mar 06 05:12 PM
Van Oene Mark	See Remarks	Mar 04 '24	Sale	4.87	9,186	44,745	1,668,826	Mar 06 05:26 PM
Kim Susan G.	See Remarks	Mar 04 '24	Sale	4.87	5,275	25,695	712,260	Mar 06 05:22 PM
Farmer Michele	See Remarks	Mar 04 '24	Sale	4.87	2,968	14,457	217,216	Mar 06 05:30 PM
MOHR MARSHALL	Director	Mar 01 '24	Option Exercise	4.45	25,000	111,250	110,000	Mar 05 04:27 PM
HENRY CHRISTIAN O	See Remarks	Feb 20 '24	Sale	5.26	1,979	10,412	1,005,078	Feb 21 06:14 PM
Kim Susan G.	See Remarks	Feb 20 '24	Sale	5.26	831	4,372	282,758	Feb 21 06:17 PM
HENRY CHRISTIAN O	See Remarks	Feb 16 '24	Sale	5.96	79,038	470,908	1,007,057	Feb 21 06:14 PM
Van Oene Mark	See Remarks	Feb 16 '24	Sale	5.96	33,560	199,950	876,611	Feb 21 06:25 PM
Kim Susan G.	See Remarks	Feb 16 '24	Sale	5.96	22,496	134,031	283,589	Feb 21 06:17 PM
Eidel Jeff	See Remarks	Feb 16 '24	Sale	5.96	15,498	92,337	431,824	Feb 21 06:20 PM
Farmer Michele	See Remarks	Feb 16 '24	Sale	5.96	7,562	45,054	101,164	Feb 21 06:07 PM
Van Oene Mark	See Remarks	Jan 09 '24	Sale	7.77	31,012	241,056	910,171	Jan 10 05:44 PM
HENRY CHRISTIAN O	See Remarks	Dec 14 '23	Sale	10.00	20,000	200,000	1,086,095	Dec 15 04:35 PM
Kim Susan G.	See Remarks	Sep 29 '23	Sale	8.44	19,257	162,471	306,085	Sep 29 06:47 PM
HENRY CHRISTIAN O	See Remarks	Sep 18 '23	Sale	10.12	96,844	980,255	1,106,095	Sep 19 04:32 PM
HENRY CHRISTIAN O	See Remarks	Sep 11 '23	Sale	10.45	10,000	104,520	1,202,939	Sep 12 04:42 PM
Eidel Jeff	See Remarks	Aug 17 '23	Sale	10.60	25,936	274,844	444,666	Aug 18 04:36 PM
HENRY CHRISTIAN O	See Remarks	Aug 17 '23	Sale	10.50	10,000	105,000	1,212,939	Aug 18 04:44 PM
Van Oene Mark	See Remarks	Aug 16 '23	Sale	11.00	26,102	287,122	939,769	Aug 18 04:26 PM

Open in Screener

MRNA

Moderna Inc

May 23 • 02:47PM ET

162.96

Dollar change -0.37
Percentage change -0.23	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI QQQ VOO VO IVV IBB VUG VOT RSP IWD

Index	NDX, S&P 500	P/E	-	EPS (ttm)	-15.68	Insider Own	12.13%	Shs Outstand	382.00M	Perf Week	22.82%
Market Cap	62.45B	Forward P/E	-	EPS next Y	-5.22	Insider Trans	-0.68%	Shs Float	336.75M	Perf Month	49.71%
Income	-5968.00M	PEG	-	EPS next Q	-3.35	Inst Own	67.38%	Short Float	6.26%	Perf Quarter	68.94%
Sales	5.14B	P/S	12.14	EPS this Y	42.93%	Inst Trans	0.89%	Short Ratio	5.44	Perf Half Y	111.25%
Book/sh	33.46	P/B	4.87	EPS next Y	25.87%	ROA	-29.22%	Short Interest	21.07M	Perf Year	18.30%
Cash/sh	22.28	P/C	7.31	EPS next 5Y	-	ROE	-37.68%	52W Range	62.55 - 164.88	Perf YTD	63.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.02%	ROI	-42.54%	52W High	-1.17%	Beta	1.59
Dividend TTM	-	Quick Ratio	3.91	Sales past 5Y	662.08%	Gross Margin	11.10%	52W Low	160.52%	ATR (14)	7.03
Dividend Ex-Date	-	Current Ratio	4.03	EPS Y/Y TTM	-227.99%	Oper. Margin	-100.04%	RSI (14)	84.89	Volatility	7.18% 5.25%
Employees	5600	Debt/Eq	0.10	Sales Y/Y TTM	-65.53%	Profit Margin	-116.00%	Recom	2.38	Target Price	136.25
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-1676.58%	Payout	-	Rel Volume	1.61	Prev Close	163.33
Sales Surprise	79.07%	EPS Surprise	13.68%	Sales Q/Q	-91.07%	Earnings	May 02 BMO	Avg Volume	3.87M	Price	162.96
SMA20	30.37%	SMA50	44.01%	SMA200	63.98%	Trades		Volume	5,139,046	Change	-0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-26-24	Downgrade	HSBC Securities	Hold → Reduce	$75 → $86
Jan-02-24	Upgrade	Oppenheimer	Perform → Outperform	$142
Nov-29-23	Initiated	Canaccord Genuity	Hold	$82
Nov-03-23	Upgrade	HSBC Securities	Reduce → Hold	$89 → $69
Nov-02-23	Downgrade	Deutsche Bank	Hold → Sell	$125 → $60
Aug-04-23	Downgrade	TD Cowen	Outperform → Market Perform	$145 → $125
Aug-03-23	Downgrade	Deutsche Bank	Buy → Hold	$125
Jul-24-23	Initiated	William Blair	Mkt Perform	$136.28
Jul-14-23	Initiated	HSBC Securities	Reduce	$97
Jun-26-23	Upgrade	UBS	Neutral → Buy	$221 → $191
Apr-26-23	Initiated	Guggenheim	Neutral
Mar-13-23	Upgrade	TD Cowen	Market Perform → Outperform	$150 → $180
Mar-02-23	Initiated	RBC Capital Mkts	Outperform	$200
Feb-24-23	Downgrade	SVB Securities	Market Perform → Underperform	$111 → $93
Dec-19-22	Upgrade	Jefferies	Hold → Buy	$170 → $275
Dec-14-22	Downgrade	Chardan Capital Markets	Buy → Neutral	$186 → $191
Oct-21-22	Upgrade	SVB Leerink	Underperform → Mkt Perform	$174 → $101
Sep-08-22	Upgrade	Deutsche Bank	Hold → Buy	$165
Feb-01-22	Upgrade	Redburn	Sell → Neutral
Jan-26-22	Upgrade	Deutsche Bank	Sell → Hold	$175

Show Previous Ratings

Today 12:45PM	Heard on the Street: Moderna Got a Boost From Bird Flu, but Dont Count Your Chicks (The Wall Street Journal)
11:34AM	The Moderna News That Has MRNA Stock Price Surging This Week: 3 Key Catalysts (InvestorPlace)
May-22-24 06:43PM	Second US Human Bird Flu Infection Reported in Michigan (Bloomberg) +13.67%
06:18PM	Moderna and Pfizer In Talks With U.S. To Make a Bird Flu Vaccine (Barrons.com)
05:28PM	CDC Confirms a Second Bird Flu Case in U.S. Dairy Worker. Vaccine Momentum Builds. (Barrons.com)
05:12PM	Loading…
05:12PM	Bird Flu Cases Spur Retail Trader Rush Into Vaccine Stocks (Bloomberg)
04:48PM	S&P 500 Gains and Losses Today: Target Falls Amid Constrained Consumer Spending (Investopedia)
03:40PM	Moderna Stock Spikes on Bird Flu Worries (Barrons.com)
01:26PM	Nvidia earnings on tap, stocks in wait-and-see mode: Yahoo Finance (Yahoo Finance Video)
07:10AM	Moderna Has Big AI News. Is the Stock a Buy? (Motley Fool)
07:00AM	Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting (ACCESSWIRE)
May-21-24 01:55PM	Final Trades: Moderna, Palantir, Oracle and Bank of America (CNBC TV)
01:34PM	3 Cathie Wood Stocks to Buy Now: May 2024 (InvestorPlace)
10:24AM	ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development (Benzinga)
May-20-24 04:54PM	S&P 500 Gains and Losses Today: Norwegian Cruise Soars on Guidance, Strategy Update (Investopedia) +6.10%
03:34PM	Loading…
03:34PM	Stocks, Gold Reach New Record Highs, Cruise Stocks Rally, GameStop Sinks: What's Driving Markets Monday? (Benzinga)
03:29PM	Moderna and Novavax Hope for Early Launch of This Years Covid-19 Shots (Barrons.com)
02:31PM	Moderna and Novavax Hope for Early Launch of This Years Covid-19 Shots, Despite FDA Delay (Barrons.com)
04:22AM	Pfizer wins cancer drug patent case against AstraZeneca (Pharmaceutical Technology)
03:35AM	Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing (MT Newswires)
May-18-24 09:32AM	Jim Cramer's Latest Stock Picks in May 2024 (Insider Monkey)
May-17-24 06:33PM	Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy? (TipRanks)
04:05PM	Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing (MT Newswires)
02:46PM	European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech (Benzinga)
01:53PM	Sector Update: Health Care Stocks Softer Friday Afternoon (MT Newswires)
01:17PM	Update: Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech (MT Newswires)
12:36PM	Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech (MT Newswires)
05:40AM	Could Novavax Become the Next Moderna? (Motley Fool)
May-16-24 10:51AM	Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game (Benzinga)
May-15-24 08:19AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:29AM	Loading…
May-14-24 11:29AM	Moderna Stock Rebounds From Its RSV Vaccine Fallout Is It A Buy, Again? (Investor's Business Daily)
06:35AM	Is This a Setback for Moderna? (Motley Fool)
05:23AM	Evercore ISI Initiates Moderna With In Line Rating, $120 Price Target (MT Newswires)
May-13-24 05:23PM	S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan (Investopedia) +7.13%
11:25AM	Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine (Zacks)
09:00AM	Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know (Zacks)
08:45AM	Bull Market and Beyond: 2 Stocks Just Waiting to Soar (Motley Fool)
07:00AM	Moderna to Present at Upcoming Conferences in May/June 2024 (ACCESSWIRE)
03:43AM	Moderna Insider Sold Shares Worth $1,825,220, According to a Recent SEC Filing (MT Newswires)
May-12-24 09:25AM	Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy? (Motley Fool)
May-10-24 04:55PM	S&P 500 Gains and Losses Today: Akamai Technologies Tumbles on Weak Guidance (Investopedia)
04:08PM	Novavax stock doubles after Sanofi deal marks 'new chapter' for company (Yahoo Finance)
04:03PM	Moderna Tumbles After The FDA Throws A Curveball On Its Second Product (Investor's Business Daily)
02:52PM	Consumer sentiment drops, Tesla's Supercharger, Zeekr IPO: Catalysts (Yahoo Finance Video)
01:24PM	Novavax CEO on Sanofi deal: 'This is a new chapter in the history of our company' (Yahoo Finance)
01:23PM	Top Stock Movers Now: TSMC, Moderna, Sweetgreen, and More (Investopedia)
12:06PM	Top Midday Stories: Biden to Reportedly Quadruple Chinese EV Tariffs; Novavax Shares Soar on Sanofi Deal News; Protesters Try to Break Into Tesla's Plant in Germany; FDA Pushes Back Approval of Moderna Vaccine (MT Newswires)
11:59AM	Moderna Stock Slips as FDA Delays RSV Vaccine Approval (Investopedia)
10:50AM	Moderna: FDA postpones RSV vaccine approval (Yahoo Finance Video)
10:39AM	Moderna Seesaws After The FDA Throws A Curveball On Its Second Product (Investor's Business Daily)
10:12AM	FDA delays decision on Moderna's RSV shot until the end of May (FierceBiotech.com)
09:13AM	Sector Update: Health Care Stocks Edge Higher Premarket Friday (MT Newswires)
09:02AM	Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine (Investor's Business Daily)
08:46AM	Moderna's RSV Vaccine Review Delayed by FDA to End of May (MT Newswires)
08:26AM	FDA Delays Decision on Moderna RSV Shot by 3 Weeks (Barrons.com)
08:04AM	Update: US FDA Delays Approval of Moderna's RSV Vaccine Biologics License Application (MT Newswires)
07:47AM	FDA delays decision on Moderna RSV vaccine (BioPharma Dive)
07:39AM	US FDA Delays Approval of Moderna's RSV Vaccine Biologics License Application (MT Newswires)
07:00AM	US FDA pushes decision on Moderna's RSV vaccine to end of this month (Reuters)
07:00AM	Moderna Announces Update on Investigational RSV Vaccine (ACCESSWIRE)
06:00AM	Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life (InvestorPlace)
May-09-24 04:17PM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:33PM	Deutsche Bank Raises Moderna's Price Target to $85 From $70 (MT Newswires)
12:31PM	Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:34AM	Moderna's Promise of mRNA Undercut by New RSV Vaccine (Bloomberg)
09:51AM	Sisk selected for MITC fit-out in Oxfordshire (World Construction Network)
09:05AM	If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today (Motley Fool)
07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
06:00AM	Modernas First Vaccine Was a Big Hit. Its Second Is a Let Down (Bloomberg)
May-08-24 12:02PM	Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat? (Investor's Business Daily)
08:30AM	Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024 (GlobeNewswire)
02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
May-07-24 11:24AM	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:36AM	UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating (MT Newswires)
May-06-24 03:20AM	Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing (MT Newswires)
May-05-24 03:00AM	Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna. (Barrons.com)
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:34AM	MSFT Analysis: Why Microsoft Stock Is a Must-Own for Investors in 2024 (InvestorPlace)
01:01AM	Decoding Moderna Inc (MRNA): A Strategic SWOT Insight (GuruFocus.com)
May-03-24 08:45AM	3 Growth Stocks You'll Kick Yourself for Not Buying Today (InvestorPlace)
08:26AM	Jefferies Adjusts Price Target on Moderna to $155 From $125 (MT Newswires)
08:24AM	Oppenheimer Adjusts Price Target on Moderna to $163 From $142 (MT Newswires)
08:21AM	Goldman Sachs Adjusts Price Target on Moderna to $204 From $206 (MT Newswires)
08:08AM	Leerink Adjusts Price Target on Moderna to $60 From $59 (MT Newswires)
07:55AM	Morgan Stanley Adjusts Price Target on Moderna to $95 From $89 (MT Newswires)
07:27AM	Jefferies & Co Adjusts Moderna Price Target to $155 From $125 (MT Newswires)
07:19AM	Goldman Sachs Adjusts Moderna Price Target to $204 From $206 (MT Newswires)
06:24AM	Morgan Stanley Raises Price Target on Moderna to $95 From $89, Keeps Equalweight Rating (MT Newswires)
06:23AM	RBC Raises Price Target on Moderna to $135 From $125 on 'More Prudent Financial Outlook,' Keeps Outperform Rating (MT Newswires)
06:15AM	Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar (InvestorPlace)
05:00AM	Wegovy sales surge, COVID vax sales sink, and 'junk' patents: Pharma news roundup (Quartz)
04:42AM	Moderna reports $1.2bn net loss in Q1 2024 (Pharmaceutical Technology)
03:04AM	Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ... (GuruFocus.com)
May-02-24 06:47PM	Analyst Report: Moderna, Inc. (Morningstar Research) +12.68%
06:36PM	Why Moderna Stock Blasted 13% Higher Today (Motley Fool)
05:23PM	S&P 500 Gains and Losses Today: Etsy Drops Amid Sluggish Discretionary Spending (Investopedia)
05:21PM	Modernas sales from its only product, the COVID-19 vaccine, fell 91% from last year (Fortune)
04:17PM	Novo Nordisk slides while Moderna pops: Tale of two pharma stocks (Yahoo Finance Video)
04:03PM	Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views (Investor's Business Daily)
03:58PM	Sector Update: Health Care Stocks Softer Late Afternoon (MT Newswires)

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoge Stephen	President	May 15 '24	Sale	127.49	15,000	1,912,350	1,471,508	May 17 04:04 PM
AFEYAN NOUBAR	Director	May 15 '24	Sale	127.32	15,000	1,909,863	1,996,931	May 17 07:00 PM
Hoge Stephen	President	May 10 '24	Sale	120.96	255	30,844	1,486,508	May 13 04:03 PM
AFEYAN NOUBAR	Director	May 08 '24	Sale	121.68	15,000	1,825,220	2,011,931	May 10 07:00 PM
AFEYAN NOUBAR	Director	May 01 '24	Sale	110.92	15,000	1,663,855	2,026,931	May 03 07:00 PM
AFEYAN NOUBAR	Director	Apr 24 '24	Sale	108.32	15,000	1,624,836	2,041,931	Apr 26 07:00 PM
AFEYAN NOUBAR	Director	Apr 17 '24	Sale	103.38	15,000	1,550,703	2,056,931	Apr 19 07:00 PM
Hoge Stephen	President	Apr 15 '24	Sale	105.02	15,000	1,575,300	1,486,241	Apr 16 04:23 PM
AFEYAN NOUBAR	Director	Apr 10 '24	Sale	107.12	15,000	1,606,865	2,071,931	Apr 12 07:00 PM
Mock James M	Chief Financial Officer	Apr 08 '24	Sale	101.93	705	71,859	5,048	Apr 09 04:09 PM
AFEYAN NOUBAR	Director	Apr 03 '24	Sale	101.68	15,000	1,525,268	2,086,931	Apr 05 07:00 PM
AFEYAN NOUBAR	Director	Mar 27 '24	Sale	109.06	15,000	1,635,864	2,101,931	Mar 29 07:00 PM
AFEYAN NOUBAR	Director	Mar 20 '24	Sale	102.39	15,000	1,535,820	2,116,931	Mar 22 07:00 PM
Hoge Stephen	President	Mar 15 '24	Sale	103.17	15,000	1,547,550	1,501,241	Mar 19 04:39 PM
AFEYAN NOUBAR	Director	Mar 13 '24	Sale	108.54	15,000	1,628,031	2,131,931	Mar 15 07:00 PM
Klinger Shannon Thyme	Chief Legal Officer	Mar 08 '24	Sale	99.05	544	53,884	9,267	Mar 11 09:05 AM
Hoge Stephen	President	Mar 04 '24	Sale	94.34	309	29,151	1,516,241	Mar 05 05:52 PM
Klinger Shannon Thyme	Chief Legal Officer	Mar 04 '24	Sale	94.34	117	11,038	8,673	Mar 05 05:56 PM
Hoge Stephen	President	Feb 29 '24	Sale	94.57	2,388	225,838	1,515,898	Mar 01 05:25 PM
Klinger Shannon Thyme	Chief Legal Officer	Feb 29 '24	Sale	94.57	670	63,363	8,557	Mar 01 05:29 PM
Mock James M	Chief Financial Officer	Feb 29 '24	Sale	94.57	647	61,188	4,300	Mar 01 05:33 PM
Hoge Stephen	President	Feb 22 '24	Sale	100.00	15,000	1,500,000	1,513,433	Feb 23 04:04 PM
Bancel Stephane	Chief Executive Officer	Feb 16 '24	Sale	88.88	26,351	2,342,098	5,460,224	Feb 16 04:10 PM
Hoge Stephen	President	Feb 16 '24	Sale	88.88	10,542	936,981	1,528,433	Feb 16 04:19 PM
Hoge Stephen	President	Feb 12 '24	Sale	86.23	304	26,214	1,516,281	Feb 13 04:13 PM
Hoge Stephen	President	Jan 16 '24	Sale	103.90	15,000	1,558,500	1,516,063	Jan 17 04:12 PM
Mock James M	Chief Financial Officer	Jan 08 '24	Sale	109.75	772	84,731	3,632	Jan 09 04:08 PM
Hoge Stephen	President	Dec 27 '23	Sale	100.01	45,000	4,500,450	1,531,063	Dec 28 08:00 AM
Klinger Shannon Thyme	Chief Legal Officer	Dec 08 '23	Sale	79.09	563	44,525	7,912	Dec 11 04:03 PM
Garay Arpa	Chief Commercial Officer	Dec 06 '23	Sale	78.34	564	44,182	3,690	Dec 07 04:21 PM
Hoge Stephen	President	Dec 04 '23	Sale	79.31	309	24,508	1,576,063	Dec 05 04:07 PM
Klinger Shannon Thyme	Chief Legal Officer	Dec 04 '23	Sale	79.31	111	8,804	7,336	Dec 05 04:10 PM
Hoge Stephen	President	Nov 29 '23	Sale	79.81	1,136	90,666	1,575,721	Nov 30 04:11 PM
Hoge Stephen	President	Nov 10 '23	Sale	68.76	263	18,084	1,574,446	Nov 13 04:02 PM
AFEYAN NOUBAR	Director	Nov 01 '23	Sale	76.00	10,000	760,032	2,146,931	Nov 03 07:00 PM
AFEYAN NOUBAR	Director	Oct 25 '23	Sale	76.99	10,000	769,854	2,156,931	Oct 27 07:00 PM
AFEYAN NOUBAR	Director	Oct 11 '23	Sale	103.30	15,000	1,549,441	2,166,931	Oct 13 07:00 PM
Mock James M	Chief Financial Officer	Oct 06 '23	Sale	102.50	2,858	292,953	2,952	Oct 10 04:51 PM
AFEYAN NOUBAR	Director	Oct 04 '23	Sale	102.72	15,000	1,540,845	2,181,931	Oct 06 07:02 PM
AFEYAN NOUBAR	Director	Sep 27 '23	Sale	98.96	10,000	989,646	2,196,931	Sep 29 07:00 PM
AFEYAN NOUBAR	Director	Sep 20 '23	Sale	104.74	15,000	1,571,090	2,206,931	Sep 22 07:00 PM
Hoge Stephen	President	Sep 15 '23	Sale	112.99	15,000	1,694,850	1,574,187	Sep 18 04:06 PM
AFEYAN NOUBAR	Director	Sep 13 '23	Sale	109.70	15,000	1,645,522	2,221,931	Sep 15 07:00 PM
Klinger Shannon Thyme	Chief Legal Officer	Sep 08 '23	Sale	107.22	557	59,722	7,215	Sep 11 04:02 PM
AFEYAN NOUBAR	Director	Sep 06 '23	Sale	107.61	15,000	1,614,094	1,982,209	Sep 08 07:01 PM
Garay Arpa	Chief Commercial Officer	Sep 06 '23	Sale	108.40	574	62,219	3,113	Sep 07 04:46 PM
Hoge Stephen	President	Sep 05 '23	Sale	111.44	320	35,660	1,589,187	Sep 06 04:08 PM
Klinger Shannon Thyme	Chief Legal Officer	Sep 05 '23	Sale	111.44	115	12,815	6,634	Sep 06 04:17 PM
AFEYAN NOUBAR	Director	Aug 30 '23	Sale	115.46	15,000	1,731,951	1,997,209	Sep 01 07:00 PM
Hoge Stephen	President	Aug 29 '23	Sale	115.01	1,135	130,542	1,588,855	Aug 30 04:07 PM
AFEYAN NOUBAR	Director	Aug 23 '23	Sale	115.51	15,000	1,732,613	2,012,209	Aug 25 07:00 PM
Hoge Stephen	President	Aug 17 '23	Sale	100.00	15,000	1,500,000	1,587,579	Aug 18 05:16 PM
AFEYAN NOUBAR	Director	Aug 16 '23	Sale	97.56	10,000	975,614	2,027,209	Aug 18 07:01 PM
Hoge Stephen	President	Aug 10 '23	Sale	102.53	247	25,325	1,602,579	Aug 11 04:18 PM
AFEYAN NOUBAR	Director	Aug 02 '23	Sale	110.99	15,000	1,664,876	2,037,209	Aug 04 07:00 PM
AFEYAN NOUBAR	Director	Jul 26 '23	Sale	120.42	15,000	1,806,229	2,052,209	Jul 28 07:05 PM
AFEYAN NOUBAR	Director	Jul 19 '23	Sale	125.48	15,000	1,882,152	2,067,209	Jul 21 07:00 PM
Hoge Stephen	President	Jul 17 '23	Sale	120.60	15,000	1,809,000	1,602,303	Jul 18 04:35 PM
AFEYAN NOUBAR	Director	Jul 12 '23	Sale	125.81	15,000	1,887,081	2,082,209	Jul 14 07:01 PM
AFEYAN NOUBAR	Director	Jul 05 '23	Sale	124.73	15,000	1,870,933	2,097,209	Jul 07 07:00 PM
Bancel Stephane	Chief Executive Officer	Jun 28 '23	Option Exercise	0.99	27,155	26,883	5,439,101	Jun 30 04:51 PM
Bancel Stephane	Chief Executive Officer	Jun 28 '23	Sale	121.63	27,155	3,302,907	5,411,946	Jun 30 04:51 PM
AFEYAN NOUBAR	Director	Jun 28 '23	Sale	121.54	15,000	1,823,160	2,112,209	Jun 30 07:02 PM
Bancel Stephane	Chief Executive Officer	Jun 22 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 23 04:03 PM
Bancel Stephane	Chief Executive Officer	Jun 22 '23	Sale	119.41	40,000	4,776,427	5,411,946	Jun 23 04:03 PM
Bancel Stephane	Chief Executive Officer	Jun 21 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 23 04:03 PM
Bancel Stephane	Chief Executive Officer	Jun 21 '23	Sale	121.98	40,000	4,879,287	5,411,946	Jun 23 04:03 PM
AFEYAN NOUBAR	Director	Jun 21 '23	Sale	121.95	15,000	1,829,227	2,127,209	Jun 23 07:01 PM
Bancel Stephane	Chief Executive Officer	Jun 15 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 16 04:15 PM
Bancel Stephane	Chief Executive Officer	Jun 15 '23	Sale	128.41	40,000	5,136,388	5,411,946	Jun 16 04:15 PM
Hoge Stephen	President	Jun 15 '23	Sale	125.93	15,000	1,888,950	1,617,303	Jun 16 04:10 PM
Bancel Stephane	Chief Executive Officer	Jun 14 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 16 04:15 PM
Bancel Stephane	Chief Executive Officer	Jun 14 '23	Sale	126.14	40,000	5,045,486	5,411,946	Jun 16 04:15 PM
AFEYAN NOUBAR	Director	Jun 14 '23	Sale	126.18	15,000	1,892,627	2,142,209	Jun 16 07:00 PM
Bancel Stephane	Chief Executive Officer	Jun 08 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 09 04:14 PM
Bancel Stephane	Chief Executive Officer	Jun 08 '23	Sale	124.01	40,000	4,960,364	5,411,946	Jun 09 04:14 PM
Klinger Shannon Thyme	Chief Legal Officer	Jun 08 '23	Sale	124.09	565	70,111	6,516	Jun 09 04:09 PM
Bancel Stephane	Chief Executive Officer	Jun 07 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 09 04:14 PM
Bancel Stephane	Chief Executive Officer	Jun 07 '23	Sale	125.81	40,000	5,032,420	5,411,946	Jun 09 04:14 PM
AFEYAN NOUBAR	Director	Jun 07 '23	Sale	125.91	15,000	1,888,601	2,157,209	Jun 09 07:00 PM
Garay Arpa	Chief Commercial Officer	Jun 06 '23	Sale	125.75	2,290	287,972	2,547	Jun 07 04:05 PM
Hoge Stephen	President	Jun 02 '23	Sale	130.32	309	40,270	1,632,303	Jun 05 04:16 PM
Klinger Shannon Thyme	Chief Legal Officer	Jun 02 '23	Sale	130.32	110	14,336	5,942	Jun 05 04:20 PM
Bancel Stephane	Chief Executive Officer	Jun 01 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 02 04:46 PM
Bancel Stephane	Chief Executive Officer	Jun 01 '23	Sale	127.96	40,000	5,118,473	5,411,946	Jun 02 04:46 PM
Bancel Stephane	Chief Executive Officer	May 31 '23	Option Exercise	0.99	40,000	39,600	5,451,946	Jun 02 04:46 PM
Bancel Stephane	Chief Executive Officer	May 31 '23	Sale	126.91	40,000	5,076,558	5,411,946	Jun 02 04:46 PM
AFEYAN NOUBAR	Director	May 31 '23	Sale	127.35	15,000	1,910,322	2,172,209	Jun 02 07:00 PM
Hoge Stephen	President	May 30 '23	Sale	124.95	1,181	147,569	1,631,961	May 31 04:21 PM
Bancel Stephane	Chief Executive Officer	May 25 '23	Option Exercise	0.99	40,000	39,600	5,451,946	May 26 04:59 PM
Bancel Stephane	Chief Executive Officer	May 25 '23	Sale	127.36	40,000	5,094,421	5,411,946	May 26 04:59 PM
Bancel Stephane	Chief Executive Officer	May 24 '23	Option Exercise	0.99	40,000	39,600	5,451,946	May 26 04:59 PM
Bancel Stephane	Chief Executive Officer	May 24 '23	Sale	131.43	40,000	5,257,212	5,411,946	May 26 04:59 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PACB

Pacific Biosciences of California Inc

MRNA

Moderna Inc

Upgrade your FINVIZ experience